- Home
- GMM vs CLYM Comparison
GMM vs CLYM Comparison
Compare GMM & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMM
- CLYM
- Stock Information
- Founded
- GMM 2017
- CLYM 2018
- Country
- GMM China
- CLYM United States
- Employees
- GMM N/A
- CLYM N/A
- Industry
- GMM
- CLYM
- Sector
- GMM
- CLYM
- Exchange
- GMM Nasdaq
- CLYM NYSE
- Market Cap
- GMM 70.8M
- CLYM 83.1M
- IPO Year
- GMM 2023
- CLYM 2021
- Fundamental
- Price
- GMM $2.43
- CLYM $1.20
- Analyst Decision
- GMM
- CLYM
- Analyst Count
- GMM 0
- CLYM 0
- Target Price
- GMM N/A
- CLYM N/A
- AVG Volume (30 Days)
- GMM 65.5K
- CLYM 117.1K
- Earning Date
- GMM 05-16-2025
- CLYM 05-14-2025
- Dividend Yield
- GMM N/A
- CLYM N/A
- EPS Growth
- GMM 62.17
- CLYM N/A
- EPS
- GMM 6.37
- CLYM N/A
- Revenue
- GMM $41,360,953.00
- CLYM N/A
- Revenue This Year
- GMM N/A
- CLYM N/A
- Revenue Next Year
- GMM N/A
- CLYM N/A
- P/E Ratio
- GMM $0.41
- CLYM N/A
- Revenue Growth
- GMM 53.82
- CLYM N/A
- 52 Week Low
- GMM $0.21
- CLYM $1.05
- 52 Week High
- GMM $4.97
- CLYM $10.86
- Technical
- Relative Strength Index (RSI)
- GMM 43.12
- CLYM N/A
- Support Level
- GMM $2.36
- CLYM N/A
- Resistance Level
- GMM $2.69
- CLYM N/A
- Average True Range (ATR)
- GMM 0.26
- CLYM 0.00
- MACD
- GMM 0.08
- CLYM 0.00
- Stochastic Oscillator
- GMM 74.00
- CLYM 0.00
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.